Need professional-grade analysis? Visit stockanalysis.com
$2.24B
N/A
N/A
N/A
Mineralys Therapeutics, Inc. Common Stock (MLYS) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $28.78, down 5.89% from the previous close.
Over the past year, MLYS has traded between a low of $12.87 and a high of $47.33. The stock has gained 112.7% over this period. It is currently 39.2% below its 52-week high.
Mineralys Therapeutics, Inc. Common Stock has a market capitalization of $2.24B.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Side-by-side comparison against top Healthcare peers.